ProQR Therapeutics (PRQR) Equity Income (2019 - 2022)

ProQR Therapeutics has reported Equity Income for 4 years, with the latest figure at -$8978.7 in Q1 2022.

• Quarterly Equity Income changed N/A year-over-year to -$8978.7 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was -$8978.7 (up 97.83% YoY) and the FY2022 annual result came in at -$8162.0, up 96.82% from the prior year.
• Equity Income improved to -$8978.7 in Q1 2022 per PRQR's latest filing, from -$97237.5 in the prior quarter.
• Over five years, Equity Income peaked at $293269.8 in Q2 2019 and troughed at -$155665.9 in Q3 2021.
• A 4-year average of $14857.4 and a median of -$33127.3 in 2020 frame the typical range for Equity Income.
• The sharpest annual moves came in 2020 and 2021: Equity Income slumped 214.31% in 2020, then sank 56.84% in 2021.
• Over 4 years, Equity Income stood at $54237.5 in 2019, then plunged by 214.31% to -$61999.1 in 2020, then slumped by 56.84% to -$97237.5 in 2021, then soared by 90.77% to -$8978.7 in 2022.
• According to Business Quant data, Equity Income over the past three periods registered -$8978.7, -$97237.5, and -$155665.9 for Q1 2022, Q4 2021, and Q3 2021 respectively.